top of page
Laboratory Data Analysis

EPIC JNJ-80202135
Clinical Study

JNJ-80202135 is a clinical study by Janssen Research & Development to determine the efficacy and safety of Nipocalimab vs. Efgartigimod for patients with Generalized Myasthenia Gravis.

This is a  a randomized, open-label, phase 3b, interventional trial which includes within class switching from Efgartigimod to Nipocalimab.   

 

To qualify, participants generally must include:

 

  • Age:  18 - 74 years 
     

  • Diagnosis:  
    Myasthenia Gravis

     

  • Patients must be AChR antibody positive
     

  • Patients test positive for generalized Myasthenia Gravis, ocular symptoms must account for less than 50% of symptoms
     

  • MG-ADL score greater than 5
     

  • Patients must be on a stable dosing regimen prior to screening 
     

Standard .Standard Clinical Study Inquiry Form to be inserted below this information like the other study pages currently online. 

bottom of page